AGN-241751

AGN-241751
Clinical data
Routes of
administration		 By mouth
Drug class NMDA receptor modulator

AGN-241751 is an orally active small-molecule NMDA receptor modulator which is under development for the treatment of major depressive disorder (MDD).[1][2] It was originated by Naurex and was acquired by Allergan from Aptinyx in May 2018.[1][2] Allergan (previously Naurex) is also developing the NMDA receptor modulators rapastinel (GLYX-13; intravenous) and apimostinel (NRX-1074, AGN-241660; oral) for the treatment of MDD.[3][4][5] Like apimostinel, AGN-241751 is intended as an oral follow-up compound to rapastinel.[2][6] As of May 2018, the drug is in phase I clinical trials.[1][2]

See also

References

  1. 1 2 3 https://adisinsight.springer.com/drugs/800031388
  2. 1 2 3 4 https://www.prnewswire.com/news-releases/allergan-exercises-option-to-acquire-compound-from-aptinyx-discovery-platform-under-ongoing-research-collaboration-300652397.html
  3. ↑ Vazquez GH, Camino S, Tondo L, Baldessarini RJ (2017). "Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics". CNS Neurol Disord Drug Targets. 16 (8): 858–869. doi:10.2174/1871527316666170728165648. PMID 28758582.
  4. ↑ https://adisinsight.springer.com/drugs/800031281
  5. ↑ https://adisinsight.springer.com/drugs/800038114
  6. ↑ http://www.pmlive.com/pharma_news/j_and_j_therapy_for_suicidal_depressives_a_breakthrough,_says_fda_1101990



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.